- Open Access
Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone
© Leung et al; licensee BioMed Central Ltd. 2011
- Received: 18 July 2011
- Accepted: 6 October 2011
- Published: 6 October 2011
Inhibition of the renin-angiotensin-aldosterone system (RAAS) slows down the progression of chronic renal diseases (CKD) including IgA nephropathy (IgAN). Herein, we studied the pathogenetic roles of aldosterone (Aldo) in IgAN.
Human mesangial cells (HMC) was activated with polymeric IgA (pIgA) from IgAN patients and the effects on the expression of RAAS components and TGF-β synthesis examined. To study the roles of RAAS in the glomerulotubular communication, proximal tubular epithelial cells (PTEC) was cultured with conditioned medium from pIgA-activated HMC with eplerenone or PD123319, the associated apoptotic event was measured by the generation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and reactive oxygen species (ROS).
Polymeric IgA up-regulated the Aldo synthesis and aldosterone synthase expression by HMC. The release of TGF-β by HMC was up-regulated synergistically by AngII and Aldo and this was inhibited by incubation of HMC with losartan plus eplerenone. Cultured PTEC express the mineralocorticoid receptor, but not synthesizing aldosterone. Apoptosis, demonstrated by cleaved PARP expression and caspase 3 activity, was induced in PTEC activated by conditioned medium prepared from HMC cultured with pIgA from IgAN patients. This apoptotic event was associated with increased generation of NADPH oxidase and ROS. Pre-incubation of PTEC with PD123319 and eplerenone achieved complete inhibition of PTEC apoptosis.
Our data suggest that AngII and Aldo, released by pIgA activated HMC, served as mediators for inducing apoptosis of PTEC in glomerulo-tubular communications. Crosstalk between AngII and Aldo could participate in determining the tubular pathology of IgAN.
- Conditioned Medium
- NADPH Oxidase
- Reactive Oxygen Species Generation
IgA nephropathy, the most common primary glomerulonephritis worldwide, is associated with a substantial risk of progression to end-stage renal failure (ESRF) . The disease runs a highly variable clinical course. A subgroup of IgAN with tubulointerstitial damage is often associated with the most rapid progression to ESRF . We have previously documented that mesangial IgA deposition induces local release of pro-inflammatory cytokines leading to glomerular inflammation [3, 4]. The renin-angiotensin system (RAS) is strongly involved in the development of progressive renal fibrosis with local AngII hyperactivity occurring in IgAN [5–7]. We had revealed that IgA from IgAN patients was capable of up-regulating the TGF-β production via increased AngII release by HMC following binding to pIgA . We further demonstrated altered expression of mesangial and tubular angiotensin receptors in response to raised intra-renal AngII in IgAN [3, 4, 9]. Although these data shed light on the importance of AngII and RAS in the pathogenesis of IgAN, a possible link between the aldosterone system and IgAN remains lacking. Aldosterone is an important mediator bearing injurious actions of the RAAS in chronic heart failure and renal disease [10–13]. Aldo promotes fibrosis and vascular toxicity in experimental animal models [14–16]. The specific action of Aldo is mediated through the mineralocorticoid receptor (MR) in the presence of 11ß-hydroxysteroid dehydrogenase type II (11ß-HSD2) . In humans, exogenous aldosterone increases circulating interleukin-6 (IL-6) concentrations and MR antagonism attenuates AngII-induced IL-6 increase , suggesting that endogenous aldosterone may contribute to the pro-inflammatory effects of AngII. AngII inhibition combined with Aldo blockade effectively reduces proteinuria in human CKD . All these evidences suggest that Aldo may also be involved in the pathophysiology of IgAN.
Reagents used for cell culture were obtained from Life Technologies (Rockville, MD, USA). Monoclonal anti-MR was obtained from Abcam (Cambridge, MA, USA). Rabbit anti-11ß-HSD2 was obtained from Cayman Chemical (Ann Arbor, MI, USA). Goat anti-CYP11B2, rabbit polyclonal anti-AT1R (AT1R) and AngII receptor subtype-II (AT2R) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-cleaved poly-(ADP-ribose)-polymerase (PARP) was obtained from Cell Signaling Technology (Beverly, CA, USA). Monoclonal anti-actin was obtained from Neomarkers (Fremont, CA, USA). F(ab')2 fragment of Alexa Fluor 488-conjugated goat anti-mouse, donkey anti-goat, goat anti-rabbit immunoglobulin G (IgG) antibodies were obtained from Invitrogen Ltd. (Paisley, UK). The Envision Plus System was obtained from Dako (Carpinteria, CA, USA). Peroxidase labeled anti-goat antibody was obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). 4',6'-diamidino-2-phenylindole hydrochloride (DAPI) was obtained from Molecular Probe (Eugene, OR, USA). Human total kidney RNA was obtained from Life Technologies Corporation (Carlsbad, CA, USA). Angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor (ACEI), eplerenone, AngII receptor antagonist and other chemicals were obtained from Sigma (St. Louis, MO, USA).
The study protocol was approved by the Research Ethics Committee of the University of Hong Kong and was carried out in accordance with the principles of Declaration of Helsinki. Twenty-seven Chinese patients (12 male and 15 female) with clinical and renal immunopathological diagnosis of primary IgAN were studied. Fifty milliliters of blood were collected from each studied subject at clinical quiescence (no macroscopic hematuria with urinary erythrocyte count < 10,000/ml in un-centrifuged urine). The serum was isolated and frozen at -20°C until for isolation of pIgA1. Twenty-two healthy subjects (10 male and 12 female), comparable in age and race, with no microscopic hematuria or proteinuria, were recruited as controls.
Purification of pIgA
Jacalin binding protein (JBP) was purified using a jacalin-agarose affinity column and pIgA was fractionated by the FPLC as described previously .
Cell Culture and Preparation of Conditioned Medium
Isolation and characterization of HMC and PTEC were performed as previously described [4, 20]. Growth arrested HMC were cultured in six-well culture plates (1 × 106 cells per well) with culture medium containing 0.5% FBS and pIgA (final concentration 0.5 mg/ml) isolated from patients with IgAN or controls for 48 hours. The conditioned medium (IgA-HMC medium) after culture were collected and kept frozen at -70°C until used. Conditioned medium from HMC cultured without the addition of IgA preparation was used as plain medium control.
Expression of MR, 11β-HSD2 or CYP11B2 in HMC and PTEC
HMC or PTEC were cultured with pIgA (0.5 mg/ml) from controls or IgAN patients, or IgA-HMC medium from IgAN patients (for PTEC only), for 6 h (for RNA expression) or 24 h (for protein determination). The expression of MR, 11β-HSD2 and CYP11B2 were determined by qPCR and immunoblotting. Expression of CYP11B2 in HMC or MR in PTEC was also examined using immunofluorescence staining.
Cell Culture Experiments
To determine the dose- or time-course of CYP11B2 expression or Aldo synthesis by HMC, growth arrested HMC were cultured with pIgA (0.125 to 2 mg/ml) or AngII (10-12 to 10-8 M) for 6 h (for RNA expression) or 48 h (for protein or Aldo assay); or with pIgA (0.5 mg/ml) or AngII (10-10 M) for 6 h to 96 h. To determine the dose course of angiotensinogen and ACE expression or AngII release by HMC, growth arrested HMC were cultured with Aldo (10-12 to 10-8 M) for 6 h (total RNA purification) or 48 h (for AngII assay). To examine whether there was synergistic effect of AngII and Aldo on TGF-β synthesis by HMC, growth arrested HMC were cultured with different concentrations of Aldo, AngII or their combination (10-12 to 10-8 M) for 48 h. For studying the role of MR and AT1R in pIgA induced TGF-β synthesis by HMC, HMC were pre-incubated with losartan (100 mM) or/and eplerenone (10 μM) one hour before addition of pIgA.
To examine the differential effect of pIgA, conditioned medium, AngII and Aldo on expression of MR or AT2R, ROS generation and NADPH oxidase activity by PTEC, growth arrested PTEC were cultured with (i) pIgA (0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted IgA-HMC medium prepared from controls or IgAN patients; (iii) Aldo (10-10 M) or (iv) AngII (10-10 M) for 6 h (for mRNA) or 48 h (for protein). PTEC were also pre-incubated with losartan (100 mM), PD123319 (10 μM), eplerenone (10 μM) or their combinations one hour before experiments for studying the role contributed by MR, AT1R or AT2R in ROS generation and caspase 3 activity induced by conditioned medium or AngII.
To determine the time-course of cleaved PARP or caspase 3 activity in PTEC, PTEC were cultured with (i) pIgA (0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted IgA-HMC medium prepared from controls or IgAN patients; (iii) Aldo (10-10 M) or (iv) AngII (10-10 M) for different time points For dose-course study, PTEC were cultured with various concentrations or dilutions of (i) pIgA from IgAN patients; (ii) IgA-HMC from controls or IgAN patients; (iii) Aldo or (iv) AngII for 48 h.
Renal tissues were obtained from eight normotensive patients with mild IgAN (grade 1) consecutively admitted for diagnostic renal biopsy with the presentation of microscopic haematuria. They had not previously received angiotensin-converting enzyme inhibitor or Ang II receptor subtype-1 (ATR1) antagonist. Control renal tissues were obtained from the intact pole of kidneys removed for single circumscribed tumor in seven normotensive subjects (comparable in age, sex and race). Glomerular and tubular expression of MR, 11β-HSD2 and CYP11B2 were detected by immunoperoxidase staining using specific antibodies. The bound monoclonal anti-MR or rabbit polyclonal anti-11β-HSD2 antibodies were visualized in brown using the Dako Envision Plus System. The bound goat anti-CYP11B2 antibodies were detected with peroxidase labeled anti-goat antibodies and visualized in brown using 3,3'-diaminodbenzidine (DAB). Negative controls were done with primary antibodies absorbed with relevant antigens before the first incubation. Two renal pathologists without prior knowledge of clinical or laboratory data evaluated the expression of MR, 11β-HSD2 and CYP11B2 using an arbitrary 0-5+ scale [4, 9].
HMC or PTEC were harvested and dissolved in protein extraction buffer containing protease inhibitor cocktails. Total protein from HMC (50 μg) or PTEC (10 μg) was electrophoresed through a 15% SDS-PAGE and then transferred to the polyvinylidene fluoride (PVDF) membrane. The membrane was incubated overnight with anti-CYP11B2 (1:1000), anti-AT2R (1:1000), anti-MR (1:1000) or anti-actin (1:1000) antibody in PBS-Tween before reacting with appropriate peroxidase-labeled secondary antibodies (Dako, Kyoto, Japan). The reaction was detected with ECL plus chemiluminescent detection reagent (Amersham Pharmacia Biotech, Uppsala, Sweden). The images were scanned and the density of the bands was quantitated using the ImageQuant software (Molecular Dynamic, Sunnyvale, CA, USA). The densitometric results were reported as average arbitrary integrated values (units) after normalization with the average arbitrary integrated values of the actin signal.
Detection of Cleaved PARP Expression in HMC and PTEC
Cell extracts were prepared from HMC or PTEC. Early apoptosis was detected by immunoblotting using monoclonal anti-PARP antibody (1:500) that recognized the 89 kDa cleaved PARP fragment. The membrane was then washed and incubated for 2 hours at room temperature with a peroxidase-labeled goat anti-mouse immunoglobulin (Dako, Kyoto, Japan). The reaction was quantitated as described in the previous section.
Primer sequences for qPCR
Forward primer sequences
Reward primer sequences
Determination of TGF-β, AngII or Aldo in Supernatant from Cultured HMC
TGF-β in supernatant from HMC culture was determined with the ELISA kits from R&D Systems (Minneapolis, MN, USA). The detection sensitivity was 32 pg/ml and the inter-batch coefficients of variation was 6.5%. AngII and Aldo were measured by an enzyme immunoassay kit (Cayman) according to the manufacturer's instruction. The minimum detectable concentration for AngII and Aldo was 1 and 7.8 pg/ml respectively with corresponding intra-assay coefficient of variation of 7 and 12.5%.
Quantification of Apoptosis, Determination of ROS and NADPH Oxidase Activity
Activation of caspase 3 in PTEC cultured with IgA-HMC conditioned medium was determined using the caspase 3 activity fluorometric immunosorbant enzyme assay kit (Roche Diagnostics) according to manufacturer's protocol. ROS generation was measured with the fluoroprobe carboxymethyl-H2-dichlorofluorescein diacetate. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was determined using an assay based on the chemiluminescence of lucigenin (bis-N-methylacridinium nitrate).
All data were expressed as means ± standard deviation (SD) unless otherwise specified. Statistical difference was analyzed with multivariate ANOVA for repeated measures. All p-values quoted are two-tailed and the significance is defined as p < 0.05.
Expression of CYP11B2 and 11β-HSD2 in HMC and Their Regulation by pIgA
Aldo Up-regulated Mesangial Release of AngII
Role of Aldo and AngII in Regulation of TGF-β Synthesis by HMC
AngII and Aldo at concentration >10-11 M individually increased TGF-β synthesis by HMC with synergistic effect (Figure 4B). Pre-incubation of HMC with either losartan or eplerenone partially reduced the pIgA-induced TGF-β synthesis by HMC (Figure 4C). The increased mesangial TGF-β synthesis induced by pIgA was completely abolished with dual blockade of losartan and eplerenone (Figure 4C).
Expression of MR, but not CYP11B2 or 11β-HSD2 by PTEC
Expression of MR, CYP11B2 or 11β-HSD2 in Human IgAN
Data on the expression of MR, CYP11B2 or 11β-HSD2 in cultured HMC or PTEC were further confirmed by immunohistochemical staining in kidney biopsies from patients with IgAN (Figure 5C). When compared with the staining results of the control biopsies, there was significantly increased expression of glomerular CYP11B2 and tubular MR in patients with IgAN (Figures 5D and 5E).
Regulation of MR and AT2R expression in PTEC
AngII, Aldo or IgA-HMC Medium from IgAN Patients Induced Apoptosis in PTEC
In this study, in vitro culture models of HMC and PTEC were used to examine Aldo synthesis by pIgA directly or through glomerular-tubular communications. The possible role of Aldo on PTEC injury and its interaction with AngII in IgAN was also elucidated. The RAS has been implicated in the development of progressive glomerulosclerosis in diabetic and non-diabetic nephropathy [22, 23]. We had previously demonstrated an increased expression of renin and TGF-β by HMC incubated with pIgA from IgAN patients . Polymeric IgA from these patients also up-regulated the Smad activity in HMC which was readily suppressed with captopril or losartan, supporting a pathogenetic role of pIgA1 in IgAN through up-regulation of the RAS and TGF-β. Growing evidence from experimental and clinical studies indicates that increased Aldo is an independent contributor to arterial injury and nephropathy . Both human and rat mesangial cells produce Aldo in culture [25, 26]. Exogenous Aldo significantly increased fibronectin production by mesangial cells . Renal TGF-ß and fibronectin are increased in Dahl salt-sensitive rat with heart failure (DSHF rat) in association with the development of glomerulosclerosis . Aldo blocker significantly suppressed renal TGF-ß expression in DSHF rat with reduced glomerulosclerosis. In vivo study also showed Aldo administration per se induced TGF-ß release and organ fibrosis independent of blood pressure . In the present study, we demonstrate that Aldo may initiate and amplify injury to HMC upon activation by pIgA in both paracrine and endocrine manner. We also reveal a vicious cycle between pIgA-induced AngII and Aldo amplifying the TGF-β synthesis via binding to AT1R and MR in cultured HMC in the setting mimicking IgAN.
Using similar in vitro culture model, we had previously demonstrated that that tumor necrosis factor-α (TNF-α) and AngII are released from mesangial cells following initial deposition of "pathogenetic" pIgA . This is followed by mesangial proliferation and glomerular infiltration of immuno-competent cells. A cross-talk network initiated by TNF-α, AngII and other soluble factors orchestrates interactions between infiltrating immuno-competent cells and the resident renal cells, forming a major driving force of tubulointerstitial injury. We further demonstrate that AngII, but not Aldo, released by pIgA-activated HMC up-regulate the expression of AT2R and MR by PTEC. The increased MR expression in PTEC is readily available for the binding to Aldo, released by the pIgA-activated HMC, to initiate the downstream events of PTEC injury. Our observation of an up-regulation of MR but not 11β-HSD2 in PTEC is intriguing. Previously, it is believed that the specificity for MR to Aldo is conferred enzymatically by the cortisol-inactivating enzyme 11β-HSD2 [29, 30]. However, recent evidence has suggested that it may not be totally true as it is improbable for the intrarenal 11β-HSD2 to convert all the glucocorticoid molecules to MR-inactive metabolites with the inexhaustible supply of steroid substrate . The current view suggests that the enzyme 11β-HSD2 does not block the glucocorticoid occupancy of MR but the ability of glucocorticoid to act as MR agonist. In the absence of the enzyme, there is intracellular redox change due to reduced generation of nicotinamide-adenine dinucleotide (NADH) from nicotinamide-adenine dinucleotide (NAD), the co-substrate for the cortisol-to-cortisone conversion [31, 32]. It has been demonstrated by patch-clamp study in isolated rabbit cardiomyocytes that under normal conditions, cortisol is an MR antagonist on the Aldo-induced transmembrane pump current. However, cortisol becomes an MR agonist, mimicking the effect of aldosterone, under redox change with instillation of oxidized glutathione . It has been suggested that MR, which are constitutively occupied by normal glucocorticoid levels, responds to changes in intracellular redox state in tissues either expressing (e.g. vascular smooth muscle cells)  or lacking 11β-HSD2 (e.g. cardiomyocytes) . We speculate that apart from the increased availability of MR expression to the up-regulated aldosterone release by pIgA-activated HMC in PTEC, cellular cortisol in PTEC may also act agonistically on the up-regulated MR in the absence of 11β-HSD2 under redox changes. The combined effect of aldosterone and cortisol via MR may eventually lead to cellular apoptosis.
Our data reveal that PTEC cultured with AngII, Aldo or IgA-HMC medium prepared from IgAN patients express increased NADPH oxidase and ROS formation. The events are associated with increased apoptosis in PTEC demonstrated by dose- and time-dependent up-regulation of cleaved PARP expression and caspase 3 activity. The primary function NADPH oxidase is to generate ROS [36, 37]. Although the NADPH oxidase was originally identified in phagocytic leukocytes, recent study discovered that this enzyme is an essential endogenous origin of cellular oxidative stress and cellular injury in other cell types . Furthermore, ROS generated by the NADPH oxidase may also modulate many intracellular redox signal transduction pathways . PTEC process all components of the NADPH oxidase complex [36, 38, 39]. The exact function of NADPH oxidase in regulating physiological and pathophysiological processes in the kidney remains unknown. Data from in vitro experiments have shown that NADPH oxidase-derived ROS mediate apoptosis in renal cells [39, 40]. AngII is an important in vivo regulator of NADPH oxidase in the kidney through activation of renal NADPH oxidase and induction of oxidative stress . Recent data from transgenic mouse model suggest that up-regulation of NADPH oxidase-dependent ROS generation is important in mediating apoptosis in renal tubular epithelial cell induced by AngII. Apart from AngII, our present study provides novel in vitro data showing that Aldo also induces NADPH oxidase expression and its dependent ROS generation by PTEC. Further in vivo experiment is needed to validate the role of Aldo in inducing PTEC apoptosis through NADPH oxidase and ROS generation.
Blockade of the RAS with ACEI or AT1R blocker protects hypertensive and diabetic kidney injuries by inhibiting the renal NADPH [41–43]. Aldo also enhances NADPH oxidase activity via translocation of the cytosolic component, p47phox, to the membrane subunits by an ERK1/2-related pathway . Aldo has also been shown to stimulate angiotensin-converting enzyme (ACE) expression which stimulates renal AngII production . Recent clinical studies indicate that Aldo blockade may provide renoprotection by decreasing proteinuria, independent of blood pressure control. The combination of ACEI and the selective Aldo blocker, eplerenone, can provide a better renal outcome with reduction of proteinuria and kidney damage than monotherapy [24, 46]. Interestingly, treatment with eplerenone alone or combining with the ACEI reduced proteinuria more effectively than the ACEI alone in human studies [47, 48]. In DSHF rat, combined therapy with eplerenone and ACEI reduced glomerulosclerosis, proteinuria and improved renal function more effectively than monotherapy . Based on the finding of up-regulated expression of MR and AT2R in PTEC by IgA-HMC medium from IgAN patients and AngII, we tested whether combined blockade of AT2R and MR could suppress pIgA-induced PTEC apoptosis through the glomerulo-tubular communication. Our present data confirm that blockade with PD123319 and eplererone abolishes NADPH-dependent ROS generation and apoptosis. Further in vivo study is needed to test whether combined AngII receptor and Aldo blockade provides a better renal outcome with reduction of proteinuria and tissue damage in IgAN.
Taken together, our in vitro data suggest that AngII and Aldo, released by pIgA1 activated HMC, are mediators for glomerulotubular crosstalk in inducing apoptosis of PTEC through NADPH dependent generation of ROS. In addition, crosstalk between AngII and Aldo could play a role in pIgA1 induced PTEC apoptosis in IgAN.
The study was supported by the General Research Fund from the Research Grant Committee (Hong Kong) [#769308].
- D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987, 64: 709-727.PubMedGoogle Scholar
- D'Amico G, Ferrario F, Rastaldi MP: Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis. 1995, 26: 124-132. 10.1016/0272-6386(95)90165-5.View ArticlePubMedGoogle Scholar
- Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN: Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int. 2005, 67: 602-612. 10.1111/j.1523-1755.2005.67116.x.View ArticlePubMedGoogle Scholar
- Chan LY, Leung JC, Tang SC, Choy CB, Lai KN: Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol. 2005, 16: 2306-2317. 10.1681/ASN.2004121117.View ArticlePubMedGoogle Scholar
- Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, Peruzzi L, Piccoli G, De Filippi PG: Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis. 1993, 21: 593-602.View ArticlePubMedGoogle Scholar
- Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, Graziotto R, Furci L, Modena F, Bernich P: Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int. 2003, 64: 149-159. 10.1046/j.1523-1755.2003.00065.x.View ArticlePubMedGoogle Scholar
- Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G: ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis. 1999, 34: 626-632. 10.1016/S0272-6386(99)70385-9.View ArticlePubMedGoogle Scholar
- Lai KN, Tang SC, Guh JY, Chuang TD, Lam MF, Chan LY, Tsang AW, Leung JC: Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol. 2003, 14: 3127-3137. 10.1097/01.ASN.0000095639.56212.BF.View ArticlePubMedGoogle Scholar
- Lai KN, Chan LY, Tang SC, Tsang AW, Li FF, Lam MF, Lui SL, Leung JC: Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int. 2004, 66: 1403-1416. 10.1111/j.1523-1755.2004.00874.x.View ArticlePubMedGoogle Scholar
- Nishiyama A, Abe Y: Aldosterone and renal injury. Nippon Yakurigaku Zasshi. 2004, 124: 101-109. 10.1254/fpj.124.101.View ArticlePubMedGoogle Scholar
- Mackenzie SM, Connell J: Hypertension and the expanding role of aldosterone. Curr Hypertens Rep. 2006, 8: 255-261. 10.1007/s11906-006-0059-y.View ArticlePubMedGoogle Scholar
- Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I: Aldosterone in progressive renal disease. Semin Nephrol. 2001, 21: 573-579. 10.1053/snep.2001.26797.View ArticlePubMedGoogle Scholar
- Connell JM, Davies E: The new biology of aldosterone. J Endocrinol. 2005, 186: 1-20. 10.1677/joe.1.06017.View ArticlePubMedGoogle Scholar
- Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996, 98: 1063-1068. 10.1172/JCI118867.PubMed CentralView ArticlePubMedGoogle Scholar
- Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003, 63: 1791-1800. 10.1046/j.1523-1755.2003.00929.x.View ArticlePubMedGoogle Scholar
- Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002, 283: H1802-1810.View ArticlePubMedGoogle Scholar
- Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ: Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006, 48: 1050-1057. 10.1161/01.HYP.0000248135.97380.76.View ArticlePubMedGoogle Scholar
- Bianchi S, Bigazzi R, Campese VM: Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005, 46: 45-51. 10.1053/j.ajkd.2005.03.007.View ArticlePubMedGoogle Scholar
- To WY, Leung JC, Lai KN: Identification and characterization of human serum alpha2-HS glycoprotein as a jacalin-bound protein. Biochim Biophys Acta. 1995, 1249: 58-64. 10.1016/0167-4838(95)00063-Z.View ArticlePubMedGoogle Scholar
- Lai KN, To WY, Li PK, Leung JC: Increased binding of polymeric lambda-IgA to cultured human mesangial cells in IgA nephropathy. Kidney Int. 1996, 49: 839-845. 10.1038/ki.1996.116.View ArticlePubMedGoogle Scholar
- Tam KY, Leung JC, Chan LY, Lam MF, Tang SC, Lai KN: In vitro enhanced chemotaxis of CD25+ mononuclear cells in patients with familial IgAN through glomerulotubular interactions. Am J Physiol Renal Physiol. 2010, 299: F359-368. 10.1152/ajprenal.00664.2009.View ArticlePubMedGoogle Scholar
- Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl. 2000, 77: S93-98.View ArticlePubMedGoogle Scholar
- Durvasula RV, Shankland SJ: The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy. Curr Hypertens Rep. 2006, 8: 132-138. 10.1007/s11906-006-0009-8.View ArticlePubMedGoogle Scholar
- Hollenberg NK: Aldosterone in the development and progression of renal injury. Kidney Int. 2004, 66: 1-9. 10.1111/j.1523-1755.2004.00701.x.View ArticlePubMedGoogle Scholar
- Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, Chrousos G: Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol. 2005, 96: 309-316. 10.1016/j.jsbmb.2005.03.005.View ArticlePubMedGoogle Scholar
- Lai L, Chen J, Hao CM, Lin S, Gu Y: Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Commun. 2006, 348: 70-75. 10.1016/j.bbrc.2006.07.057.View ArticlePubMedGoogle Scholar
- Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T: Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007, 22: 1314-1322. 10.1093/ndt/gfl780.View ArticlePubMedGoogle Scholar
- Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH: Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol. 2004, 286: F1059-1062. 10.1152/ajprenal.00202.2003.View ArticlePubMedGoogle Scholar
- Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988, 242: 583-585. 10.1126/science.2845584.View ArticlePubMedGoogle Scholar
- Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C: Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet. 1988, 2: 986-989.View ArticlePubMedGoogle Scholar
- Funder JW: Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009, 53: 286-290.View ArticlePubMedGoogle Scholar
- Fjeld CC, Birdsong WT, Goodman RH: Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA. 2003, 100: 9202-9207. 10.1073/pnas.1633591100.PubMed CentralView ArticlePubMedGoogle Scholar
- Funder JW: RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005, 93: 121-125. 10.1016/j.jsbmb.2004.12.010.View ArticlePubMedGoogle Scholar
- Alzamora R, Michea L, Marusic ET: Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 2000, 35: 1099-1104.View ArticlePubMedGoogle Scholar
- Mihailidou AS, Loan Le TY, Mardini M, Funder JW: Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009, 54: 1306-1312. 10.1161/HYPERTENSIONAHA.109.136242.View ArticlePubMedGoogle Scholar
- Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007, 87: 245-313. 10.1152/physrev.00044.2005.View ArticlePubMedGoogle Scholar
- Jiang F: NADPH oxidase in the kidney: a Janus in determining cell fate. Kidney Int. 2009, 75: 135-137. 10.1038/ki.2008.478.View ArticlePubMedGoogle Scholar
- Gill PS, Wilcox CS: NADPH oxidases in the kidney. Antioxid Redox Signal. 2006, 8: 1597-1607. 10.1089/ars.2006.8.1597.View ArticlePubMedGoogle Scholar
- Lodha S, Dani D, Mehta R, Bhaskaran M, Reddy K, Ding G, Singhal PC: Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med. 2002, 8: 830-840.PubMed CentralPubMedGoogle Scholar
- Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006, 55: 225-233. 10.2337/diabetes.55.01.06.db05-0894.View ArticlePubMedGoogle Scholar
- Tojo A, Asaba K, Onozato ML: Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets. 2007, 11: 1011-1018. 10.1517/1472822.214.171.1241.View ArticlePubMedGoogle Scholar
- Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002, 61: 186-194. 10.1046/j.1523-1755.2002.00123.x.View ArticlePubMedGoogle Scholar
- Hanna IR, Taniyama Y, Szocs K, Rocic P, Griendling KK: NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal. 2002, 4: 899-914. 10.1089/152308602762197443.View ArticlePubMedGoogle Scholar
- Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S: Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004, 43: 841-848. 10.1161/01.HYP.0000118519.66430.22.View ArticlePubMedGoogle Scholar
- Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T: Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001, 104: 137-139.View ArticlePubMedGoogle Scholar
- Sato A, Saruta T, Funder JW: Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006, 29: 211-216. 10.1291/hypres.29.211.View ArticlePubMedGoogle Scholar
- Brennan BJ, Martin NE: Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. J Am Pharm Assoc (2003). 2004, 44: 604-610. 10.1331/1544-3126.96.36.1994.Brennan.View ArticleGoogle Scholar
- Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004, 93: 990-996. 10.1016/j.amjcard.2004.01.007.View ArticlePubMedGoogle Scholar
- Lai KN, Chan LY, Leung JC: Mechanisms of tubulointerstitial injury in IgA nephropathy. Kidney Int Suppl. 2005, S110-115.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.